Eylea's Dosing Regimen Is Key Question As FDA Takes Draft Labeling To Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory panel to consider a bi-monthly dosing scheme for Regeneron's wet AMD and how to handle potential elevations in intraocular pressure at June 17 meeting.
You may also be interested in...
Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June
Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Positive results of two Phase III studies show VEGF Trap-Eye candidate has potential for dosing every two months, but competing against Roche's Lucentis and off-label Avastin won't be easy.